Relevant bibliographies by topics / Venom allergy

Academic literature on the topic 'Venom allergy'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Venom allergy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Venom allergy"

1

Grosch, Johannes, Bernadette Eberlein, Sebastian Waldherr, Mariona Pascal, Clara San Bartolomé, Federico De La Roca Pinzón, Michael Dittmar, et al. "Characterization of New Allergens from the Venom of the European Paper Wasp Polistes dominula." Toxins 13, no. 8 (August 10, 2021): 559. http://dx.doi.org/10.3390/toxins13080559.

Full text
Abstract:
Discriminating Polistes dominula and Vespula spp. venom allergy is of growing importance worldwide, as systemic reactions to either species’ sting can lead to severe outcomes. Administering the correct allergen-specific immunotherapy is therefore a prerequisite to ensure the safety and health of venom-allergic patients. Component-resolved diagnostics of Hymenoptera venom allergy might be improved by adding additional allergens to the diagnostic allergen panel. Therefore, three potential new allergens from P. dominula venom—immune responsive protein 30 (IRP30), vascular endothelial growth factor C (VEGF C) and phospholipase A2 (PLA2)—were cloned, recombinantly produced and biochemically characterized. Sera sIgE titers of Hymenoptera venom-allergic patients were measured in vitro to assess the allergenicity and potential cross-reactivity of the venom proteins. IRP30 and VEGF C were classified as minor allergens, as sensitization rates lay around 20–40%. About 50% of P. dominula venom-allergic patients had measurable sIgE titers directed against PLA2 from P. dominula venom. Interestingly, PLA2 was unable to activate basophils of allergic patients, questioning its role in the context of clinically relevant sensitization. Although the obtained results hint to a questionable benefit of the characterized P. dominula venom proteins for improved diagnosis of venom-allergic patients, they can contribute to a deeper understanding of the molecular mechanisms of Hymenoptera venoms and to the identification of factors that determine the allergenic potential of proteins.
APA, Harvard, Vancouver, ISO, and other styles
2

Engin, Ayse, Fatma B. Oktelik, Aslı Gelincik, Aytul Sin, Betul A. Sin, Berna A. Dursun, Sengul Beyaz, Begum Gorgulu, Esin Cetin, and Gunnur Deniz. "The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice." Allergy and Asthma Proceedings 42, no. 4 (July 1, 2021): 350–56. http://dx.doi.org/10.2500/aap.2021.42.210024.

Full text
Abstract:
Background: Hymenoptera venom allergy is an immunoglobulin (Ig) E mediated hypersensitivity reaction to Hymenoptera venoms. Obvious identification of the culprit insect that causes the clinical symptoms and, hence, the accurate selection of venom for curative treatment, is of great importance for the effectiveness and safety of venom immunotherapy. Objective: In this study, the contribution of component-resolved diagnostics (CRD) is evaluated in the diagnosis of Hymenoptera venom allergy. Method: Ninety-three patients from four different centers in Turkey were included in the study. Conventional tests, including prick and intradermal skin tests, with commercial venom extracts and serum specific IgE (sIgE) levels for whole venoms were performed. An sIgE analysis for venom allergen components, including rApi m 1, rApi m 2, rApi m 10, rVes v 1, rVes v 5, were evaluated by immunoblotting. Results: In conventional test results, 17 of 35 patients with bee venom allergy were positive to honey bee venom, whereas 18 patients were positive to bee and wasp venoms. In 28 of 35 patients with bee venom allergy, the diagnosis was confirmed with CRD. CRD revealed a sensitivity of 80% in patients with bee venom allergy. According to conventional tests, 7 of 24 patients with vespid venom allergy demonstrated sensitivity only to Vespula species, whereas 17 patients revealed double positivity. The total diagnostic sensitivity of Ves v 1 and Ves v 5 was calculated as 87.5%. Ten of 23 patients with a history of hypersensitivity to both venoms showed double sensitivity with CRD; one patient had cross-reactivity, one patient was found to be sensitive only to bee venom, and, eight patients were sensitive only to Vespula species. Eleven patients had an uncertain history in terms of the culprit insect type and six of them had double sensitivity in CRD. Conclusion: CRD seemed to be more helpful in diagnosing vespid venom allergy than bee venom allergy. It can also discriminate clinically significant sensitizations from irrelevant ones.
APA, Harvard, Vancouver, ISO, and other styles
3

Pfender, Nikolai, Ralf Lucassen, Nadine Offermann, Johannes Schulte-Pelkum, Margrit Fooke, and Thilo Jakob. "Evaluation of a Novel Rapid Test System for the Detection of Specific IgE to Hymenoptera Venoms." Journal of Allergy 2012 (February 27, 2012): 1–7. http://dx.doi.org/10.1155/2012/862023.

Full text
Abstract:
Background. The Allergy Lateral Flow Assay (ALFA) is a novel rapid assay for the detection of sIgE to allergens. The objective of this study is the evaluation of ALFA for the detection of sIgE to bee venom (BV) and wasp venom (WV) in insect venom allergic patients. Methods. Specific IgE to BV and WV was analyzed by ALFA, ALLERG-O-LIQ, and ImmunoCAP in 80 insect venom allergic patients and 60 control sera. Sensitivity and specificity of ALFA and correlation of ALFA and ImmunoCAP results were calculated. Results. The sensitivity/specificity of ALFA to the diagnosis was 100%/83% for BV and 82%/97% for WV. For insect venom allergic patients, the Spearman correlation coefficient for ALFA versus ImmunoCAP was 0.79 for BV and 0.80 for WV. However, significant differences in the negative control groups were observed. Conclusion. ALFA represents a simple, robust, and reliable tool for the rapid detection of sIgE to insect venoms.
APA, Harvard, Vancouver, ISO, and other styles
4

Grosch, Johannes, Christiane Hilger, Maria Beatrice Bilò, Stephanie Kler, Maximilian Schiener, Gunnar Dittmar, François Bernardin, et al. "Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket)." Toxins 12, no. 5 (May 14, 2020): 323. http://dx.doi.org/10.3390/toxins12050323.

Full text
Abstract:
Allergic reactions to stings of Hymenoptera species can have serious or even fatal consequences. If the identification of the culprit insect is possible, venom-specific immunotherapy effectively cures Hymenoptera venom allergies. Although component-resolved diagnostics has strongly evolved in recent years, the differentiation between allergies to closely related species such as Polistes dominula and Vespula spp. is still challenging. In order to generate the basis for new diagnostic and therapeutic strategies, this study aims at resolving the venom proteomes (venomes) of these species. The venoms of P. dominula and Vespula spp. (V. germanica, V. vulgaris) were analyzed by liquid chromatography-mass spectrometry. Resulting proteins were characterized regarding their function, localization and biochemical properties. The analyses yielded 157 proteins in Vespula spp. and 100 in P. dominula venom; 48 proteins, including annotated allergens, were found in both samples. In addition to a variety of venom trace molecules, new allergen candidates such as icarapin-like protein and phospholipase A2 were identified. This study elucidates the venomes of closely related allergy-eliciting Hymenoptera species. The data indicates that relying on marker allergens to differentiate between P. dominula and Vespula spp. venom allergy is probably insufficient and that strategies using cross-reactive major allergens could be more promising.
APA, Harvard, Vancouver, ISO, and other styles
5

Burzyńska, Marta, and Dorota Piasecka-Kwiatkowska. "A Review of Honeybee Venom Allergens and Allergenicity." International Journal of Molecular Sciences 22, no. 16 (August 4, 2021): 8371. http://dx.doi.org/10.3390/ijms22168371.

Full text
Abstract:
Honeybee venom is a source of proteins with allergenic properties which can result in in various symptoms, ranging from local reactions through to systematic life-threatening anaphylaxis, or even death. According to the World Allergy Organization (WAO), honeybee venom allergy is one of the most common causes of anaphylaxis. Among the proteins present in honeybee venom, 12 protein fractions were registered by the World Health Organization’s Allergen Nomenclature Sub-Committee (WHO/IUIS) as allergenic. Most of them are highly immunogenic glycoproteins that cross-react with IgE and, as a consequence, may give false positive results in allergy diagnosis. Allergenic fractions are different in terms of molecular weight and biological activity. Eight of these allergenic fractions have also been identified in honey. This explains frequent adverse reactions after consuming honey in people allergic to venom and sheds new light on the causes of allergic symptoms in some individuals after honey consumption. At the same time, it also indicates the possibility of using honey as a natural source of allergen in specific immunotherapy.
APA, Harvard, Vancouver, ISO, and other styles
6

Matysiak, Joanna, Eliza Matuszewska, Kacper Packi, and Agnieszka Klupczyńska-Gabryszak. "Diagnosis of Hymenoptera Venom Allergy: State of the Art, Challenges, and Perspectives." Biomedicines 10, no. 9 (September 2, 2022): 2170. http://dx.doi.org/10.3390/biomedicines10092170.

Full text
Abstract:
Hymenoptera venom allergy is the most common cause of anaphylaxis in adults and the second-most frequent in children. The proper diagnosis of this life-threatening allergy remains a challenge. This review focuses on the current knowledge regarding diagnostics of Hymenoptera venom allergy. The paper includes a brief description of the representatives of Hymenoptera order and the composition of their venoms. Then, diagnostic tests for allergy to Hymenoptera venom are described. Common diagnostic problems, especially double positivity in tests for IgE antibodies specific to honeybee and wasp venom, are also discussed. Special attention is paid to the search for new diagnostic capabilities using modern methodologies. Multidimensional molecular analysis offers an opportunity to characterize changes in body fluids associated with Hymenoptera venom allergy and yields a unique insight into the cell status. Despite recent developments in the diagnostics of Hymenoptera venom allergy, new testing methodologies are still needed to answer questions and doubts we have.
APA, Harvard, Vancouver, ISO, and other styles
7

Cui, Le, Ying-Yang Xu, Xiu-Jie Wang, and Kai Guan. "Stinging Insect Allergens." Current Protein & Peptide Science 21, no. 2 (March 10, 2020): 142–52. http://dx.doi.org/10.2174/1389203720666191120130209.

Full text
Abstract:
Hymenoptera venom allergy is one of the common causes of anaphylaxis. However, when physicians make the diagnosis of Hymenoptera venom allergy, the history of being stung is not always consistent with the results of venom-specific IgE. With the development of component-resolved diagnosis, it is possible to accurately localize an allergic reaction to certain sensitized proteins. This paper reviewed the studies that have addressed the identified allergenicity and cross-reactivity of Hymenoptera venom allergens accepted by the WHO/IUIS Nomenclature Sub-committee, the componentresolved diagnosis of Hymenoptera venom allergy and its predictive values for the efficacy and safety of venom immunotherapy. Also special attention was paid to the spread of Hymenoptera venom allergy in Asian countries.
APA, Harvard, Vancouver, ISO, and other styles
8

Stitt, Jenny, and Rohit Katial. "Venom Allergy." Journal of Allergy and Clinical Immunology: In Practice 4, no. 1 (January 2016): 184–85. http://dx.doi.org/10.1016/j.jaip.2015.09.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kholi-Wiesner, A., L. Stahlberger, C. Bieli, T. Stricker, and R. Lauener. "Bee venom allergy immunotherapy/wasp venom allergy immunotherapy." Reactions Weekly &NA;, no. 1407 (June 2012): 13. http://dx.doi.org/10.2165/00128415-201214070-00044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Worm, Margitta, Barbara Ballmer-Weber, Randolf Brehler, Mandy Cuevas, Anna Gschwend, Karin Hartmann, Thomas Hawranek, et al. "Healthcare provision for insect venom allergy patients during the COVID-19 pandemic." Allergo Journal International 29, no. 8 (December 2020): 257–61. http://dx.doi.org/10.1007/s40629-020-00157-z.

Full text
Abstract:
AbstractThe population prevalence of insect venom allergy ranges between 3–5%, and it can lead to potentially life-threatening allergic reactions. Patients who have experienced a systemic allergic reaction following an insect sting should be referred to an allergy specialist for diagnosis and treatment. Due to the widespread reduction in outpatient and inpatient care capacities in recent months as a result of the COVID-19 pandemic, the various allergy specialized centers in Germany, Austria, and Switzerland have taken different measures to ensure that patients with insect venom allergy will continue to receive optimal allergy care. A recent data analysis from the various centers revealed that there has been a major reduction in newly initiated insect venom immunotherapy (a 48.5% decline from March–June 2019 compared to March–June 2020: data from various centers in Germany, Austria, and Switzerland). The present article proposes defined organizational measures (e.g., telephone and video appointments, rearranging waiting areas and implementing hygiene measures and social distancing rules at stable patient numbers) and medical measures (collaboration with practice-based physicians with regard to primary diagnostics, rapid COVID-19 testing, continuing already-initiated insect venom immunotherapy in the outpatient setting by making use of the maximal permitted injection intervals, prompt initiation of insect venom immunotherapy during the summer season, and, where necessary, using outpatient regimens particularly out of season) for the care of insect venom allergy patients during the COVID-19 pandemic.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Venom allergy"

1

Yu, Yan. "Anti-IgE autoantibodies in bee venom allergy /." [S.l.] : [s.n.], 1991. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wu, Qi Xuan. "Immunobiology of peptides from venom of the jumper ant Myrmecia pilosul." Thesis, The University of Sydney, 2001. https://hdl.handle.net/2123/28045.

Full text
Abstract:
Ants from genus Myrmecia, subfamily Myrmeciinae, are aggressive stinging insects with medical importance in Australia, especially in the endemic areas of southeast Australia and Tasmania. Venoms of Myrmecia ants can cause allergic reactions with symptoms ranging from local to systemic. In some sensitized individuals of extreme severity, even death can occur. Two major allergens, Myr p 1 and Myr p 2 had been cloned and characterized from venom of one species, Myrmecia pilosula. The aim of this thesis was to study several aspects of the allergens from venoms of Myrmecia ants.
APA, Harvard, Vancouver, ISO, and other styles
3

Perez-Riverol, Amilcar. "Recombinant phospholipase A1 from Polybia paulista wasp venom for molecular diagnosis of allergy /." Rio Claro, 2017. http://hdl.handle.net/11449/151777.

Full text
Abstract:
Orientador: Márcia Regina Brochetto Braga
Coorientador: Mário Sergio Palma
Banca: Henrique Ferreira
Banca: Ricardo de Lima Zollner
Banca: Rogilene Aparecida Prado
Resumo: A fosfolipase A1 é um dos principais alérgenos identificados no veneno do Polybia paulista (Hymenoptera: Vespidae), uma vespa social de elevada importância clínica no sudeste do Brasil. A produção recombinante deste alérgeno contribuirá com o desenvolvimento do diagnóstico molecular de alergia. Neste trabalho é descrita a produção recombinante da fosfolipase A1 de P. paulista (rPoly p 1) no sistema celular Escherichia coli. Elevados níveis da rPoly p 1 na forma insolúvel foram obtidos após expressão na bactéria. A otimização das condições de solubilização permitiu incrementar os níveis de recuperação do alérgeno recombinante. A rPoly p 1 foi purificada (99%) até homogeneidade mediante cromatografia de afinidade em coluna de Ni2+, mostrando valores de rendimento finais de 1.5 g/L de meio de cultura. A forma nativa do alérgeno (nPoly p 1) foi purificada mediante cromatografia de troca catiônica. A rPoly p 1 foi reconhecida pela IgE específica de soros de pacientes sensibilizados ao veneno de P. paulista. O uso da rPoly p 1 permite diferenciar a ocorrência de real dupla sensibilização ao veneno de vespa e formiga ou vespa e abelha da incidência de reatividade cruzada. Soros de pacientes com IgE específica ao veneno de abelha e formiga não reagiram com a rPoly p 1, enquanto que soros de camundongos sensibilizados com rPoly p 1 apresentaram reatividade cruzada exclusivamente com fosfolipases A1 (PLA1) de vespas Neotropicais ou de climas temperados. O alinhamento múltiplo do modelo... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Phospholipase A1 (PLA1) is one of the major allergens identified in the venom Polybia paulista (Hymenoptera: Vespidae), a clinically relevant social wasp from Brazil Southeast. The recombinant production of this allergen could result in the development of molecular diagnosis of allergy thus improving the outcomes of venom immunotherapy (IT). Here, we describe the heterologous production of the PLA1 from P. paulista venom in Escherichia coli. High levels of the insoluble recombinant allergen (rPoly p 1) were obtained after expression in the prokaryotic system. The downstream optimization of the solubilization process resulted in high levels of protein recovery. The rPoly p 1 was purified to homogeneity (99%) using an immobilized Ni2+ metal affinity chromatography while a single-step cation-exchange chromatography allowed the purification of native Poly p 1 (nPoly p 1) from the venom glands. Immunoblotting analyses showed the IgE-mediated recognition of the rPoly p 1 by sera from patients sensitized to P. paulista venom. The rPoly p 1 could allow the differentiation of true double sensitization to wasp/bee and wasp/ant venoms from cross-reactivity. The sera from patients with monosensitization to honey bee or fire ant venoms do not cross-reacted with the recombinant allergen. Meanwhile, the sera from rPoly p 1-sensitized mice cross-reacted with venoms of other clinically relevant wasps from Neotropical and temperate regions. The alignment of the 3-D model from rPoly p 1 with the PLA1s from some of these wasps suggested the presence of homologues epitopes as the molecular basis for the cross-reactivity. The presence of cross-reactive carbohydrates determinants (CCDs) in the venom of several Brazilian wasps, which is a major issue for understanding the incidence of cross-reactivity during diagnosis, was also analyzed. Overall, the results described .. (Complete abstract click electronic access below)
Doutor
APA, Harvard, Vancouver, ISO, and other styles
4

Brown, Simon Geoffrey Archer, and simon brown@uwa edu au. "Preventing anaphylaxis to venom of the jack jumper ant (Myrmecia pilosula)." Flinders University. School of Medicine, 2003. http://catalogue.flinders.edu.au./local/adt/public/adt-SFU20050707.103356.

Full text
Abstract:
Background: Myrmecia pilosula (the jack jumper ant, JJA) is the principal cause of ant venom anaphylaxis in Australia. Whereas honeybee and wasp venom allergy can be treated by venom immunotherapy (VIT), no such treatment is available for ant sting allergy. In addition, information on the natural history of JJA sting allergy is required to identify those most likely to benefit from immunotherapy. The main objectives of this research were to establish: (i) the prevalence, natural history and determinants of reaction severity for JJA allergy, and; (ii) the efficacy and tolerability of JJA VIT. Methods: A search of the Royal Hobart Hospital (RHH) forensic register, a random telephone survey, and a review of emergency department (ED) presentations were performed. Three hundred eighty-eight JJA allergic volunteers were assessed, including serum venom-specific IgE RAST, and then followed up for accidental stings over a 4-year period. Finally, a randomised double-blind, placebo-controlled, crossover trial of JJA VIT was performed. Laboratory parameters measured during the trial were; leukocyte stimulation index (SI), IL-4 production, IgE RAST, histamine release test (HRT), leukotriene release test (LRT) and basophil activation test (BAT). Intradermal venom skin testing (VST) was also performed at trial entry. Findings: The prevalence of JJA sting allergy was 2.7% in the Tasmanian population, compared to 1.4% for honeybee. People aged 35 or older had a greater risk of both sting allergy and hypotensive reactions. Four deaths were identified, all in adults with significant comorbidities. During follow-up, 79 (70%) of 113 accidental jack jumper stings caused systemic reactions. Only prior worst reaction severity predicted the severity of follow-up reactions, with the majority of people experiencing similar or less severe reactions when stung again. Sixty-eight otherwise healthy JJA allergic adult volunteers were enrolled in the clinical trial. Systemic reactions to therapy were recorded in 34% during VIT. Objectively defined systemic reactions to sting challenges arose in 1/35 after VIT (mild self-limiting urticaria only) versus 21/29 in the placebo group. Treatment with oxygen, intravenous adrenaline infusion and volume resuscitation was effective and well tolerated. Hypotension was always accompanied by a relative bradycardia, which was severe and treated with atropine in two patients. In the placebo group, only VST and HRT were predictive of sting challenge results. Although IgE RAST, leukocyte SI and IL-4 production, LRT and BAT all correlated well with VST, they did not predict sting challenge outcome. After successful VIT, venom-induced leukocyte IL-4 production tended to fall, whereas IgE RAST increased and a natural decline in HRT reactivity was reversed. Interpretation: VIT is highly effective in prevention of JJA sting anaphylaxis and is likely to be of most benefit to people with a history of severe systemic reactions, which usually occur in people aged over 35. Neurocardiogenic mechanisms &/or direct cardiac effects may be important factors in some anaphylaxis deaths. Systemic reactions to immunotherapy are common and require immediate access to resuscitation facilities. The HRT warrants further investigation as a test for selecting those most likely to benefit from VIT. None of the tests evaluated appear to be reliable markers of successful VIT.
APA, Harvard, Vancouver, ISO, and other styles
5

Bantleon, Frank I. [Verfasser], and Reinhard [Akademischer Betreuer] Bredehorst. "Molecular evaluation of IgE reactivity in Hymenoptera venom allergy / Frank I. Bantleon. Betreuer: Reinhard Bredehorst." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2014. http://d-nb.info/1051435560/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ferro, Karla Priscila Vieira 1981. "Imunoterapia específica = efeitos sobre granulócitos de pacientes alérgicos ao veneno de Apis Mellifera." [s.n.], 2011. http://repositorio.unicamp.br/jspui/handle/REPOSIP/309580.

Full text
Abstract:
Orientador: Ricardo de Lima Zollner
Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-19T07:59:14Z (GMT). No. of bitstreams: 1 Ferro_KarlaPriscilaVieira_D.pdf: 2593573 bytes, checksum: dbc61c553ff3b0a43d9d67bfd357abee (MD5) Previous issue date: 2011
Resumo: As reações alérgicas à ferroada de inseto resultam de resposta exacerbada do sistema imune, com produção de elevados níveis de anticorpos IgE alérgeno-específicos e padrão de citocinas Th2, envolvidas na diferenciação de linfócitos B específicos para aquele antígeno em células produtoras de IgE e recrutamento de células efetoras da resposta alérgica. Neste contexto, granulocitos são células efetoras importantes na fase tardia da resposta alérgica e estão envolvidos na patogênese de diferentes doenças. Eosinófilos e neutrófilos, especificamente, modulam a resposta imune por meio de diferentes mecanismos, como a secreçao de citocinas, quimiocinas e mediadores lipídicos. A IgE desempenha papel central na patogênese das doenças alérgicas, interagindo com dois receptores de membranas: alta afinidade FcsRI e baixa afinidade FcsRII (CD23). A ligação da IgE ao seu receptor em mastocitos e basófilos promove a liberação de mediadores inflamatórios, dentre eles, a histamina. A histamina além de induzir os sintomas agudos da reação alérgica, sustenta a reação inflamatória até a fase crônica, sendo estes efeitos mediados através da ativação de diferentes receptores (H1, H2, H3 e H4). Os fatores liberadores de histamina (HRF), particularmente, HRF-dependentes de IgE, induzem a liberação de histamina na fase tardia da resposta alérgica, permitindo a perpetuação dos eventos inflamatórios crônicos. Muitos estudos demonstram a eficácia da imunoterapia específica na dessensibilização e no desenvolvimento de tolerância em indivíduos com quadros graves de hipersensibilidade à ferroada de insetos, sobretudo da classe Hymenoptera. Com base nestas informações, foram objetivos do presente trabalho avaliar os efeitos modulatórios da imunoterapia sobre a expressão gênica dos receptores de histamina (H1, H2 e H4), HRF- IgE dependente e de fatores apoptóticos (Bcl-2 e BID) por RT-PCR, além da expressão gênica, através da técnica de PCR em tempo real de fatores de transcrição envolvidos na diferenciação de granulocitos como PU.1, C/EBPa, C/EBPpe GATA-1, receptores de alta (FcsRla e FcsRly) e baixa afinidade de IgE (CD23), cuja detecção protéica foi realizada por imunofluorescência e citometria de fluxo, respectivamente. Além disso, foram avaliados os níveis séricos de IgE específica, secreçao de RANTES e IL-8 nos sobrenadantes das culturas celulares e quantificação de granulocitos apoptóticos através da técnica de TÚNEL. Os granulocitos foram isolados de pacientes submetidos à imunoterapia específica ao veneno de abelha, em diferentes períodos do tratamento (Pré, 1, 3, 6, 12, 18 e 24 meses), após injeção subcutânea, e submetidas à cultura por 72 horas, com estimulo de 1 ng/mL veneno de abelha. Indivíduos não alérgicos foram estudados como grupo controle. De maneira geral, a imunoterapia específica ao veneno de abelha foi capaz de modular os elementos analisados, reduzindo significativamente a expressão dos mesmos ao final de 24 meses de tratamento. Não verificamos, apenas, modulação no número de granulocitos apoptóticos ao longo da imunoterapia. Nossos resultados inéditos fornecem informações adicionais sobre os efeitos da imunoterapia sobre granulocitos, reforçando as propriedades supressoras e tolerogênicas desta forma de tratamento
Abstract: Allergic reactions to insect stings results from a exacerbated response of the immune system, resulting in the production of high levels of allergen-specific IgE antibodies and Th2 cytokine pattern, which are involved in the differentiation process of B lymphocytes, specific for that antigen, into IgE producing cells and the recruitment of effector cells of allergic response. Eosinophils and neutrophils, specifically, modulate the immune response through different mechanisms, such as the secretion of cytokines, chemokines and lipid mediators. IgE plays a central role on allergic diseases pathogenesis, interacting with two membrane receptors: high affinity FcsRI and low affinity FcsRII (CD23). Biding of IgE with receptors on mast cells and eosinophils promotes the release of inflammatory mediators, among them, histamine. Histamine, besides inducing acute symptoms of allergic reaction, supports inflammatory response until its chronic stage; these effects are mediated through the activation of distinct receptors (H1, H2, H3 and H4). Histamine releasing factors (HRF), particularly, IgE dependent HRF, induce histamine release during the late phase of allergic response, allowing the perpetuation of chronic inflammatory events. In this context, many studies have demonstrated the efficacy of specific immunotherapy on desensitization and tolerance development in subjects with severe hypersensivity to insect stings, especially Hymenoptera. Based on all these information, the aim of the present study were to evaluate the modulating effects of immunotherapy on gene expression of histamine receptors (H1, H2 and H4), IgE dependent HRF and apoptotic factors (Bcl-2 and BID), through RT-PCR; in addition to gene expression, through real time PCR, transcriptional factors involved at granulocytes differentiation as of PU.1, C/EBPa, C/EBPp and GATA-1, and protein expression of high (FcsRIa e FcsRly)and low affinity (CD23) IgE receptors, assessed by immunofluorescence and flow cytometry, respectively. Serum levels of specific IgE were also assessed, along with RANTES and IL-8 secretion in cell culture supernatant and quantification of apoptotic granulocytes through TUNEL technique. Granulocytes were isolated from patients undergoing bee venom specific immunotherapy in different periods of treatment (Pre, 1, 3, 6, 12, 18 and 24 months), after subcutaneous injection, and cultured for 72 hours, with bee venom 1ng/ml_. Non allergic subjects were studied as control group. Overall, bee venom specific immunotherapy was able to modulate the analyzed elements, significantly reducing their expression at the end of 24 months of treatment. Modulation on the number of apoptotic granulocytes were not observed during immunotherapy. Our results provide additional information about the effects of immunotherapy over granulocytes, reinforcing the suppressor and tolerogenic properties of this treatment
Doutorado
Ciencias Basicas
Doutor em Clínica Médica
APA, Harvard, Vancouver, ISO, and other styles
7

Tarzi, Michael David. "HLA-DR characterised T cell peptides of PLAâ‚‚ as a potential treatment for allergy to honeybee venom." Thesis, Imperial College London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.433483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Trevizan, Giovanna. "Imunoterapia especifica = efeitos sobre expressão de receptores de histamina, fator de liberação de histamina, GATA-3 e cadeia y do receptor de alta afinidade de IgE em celulas linfomononucleares de pacientes alergicos ao veneno de Apis mellifera." [s.n.], 2010. http://repositorio.unicamp.br/jspui/handle/REPOSIP/311765.

Full text
Abstract:
Orientador: Ricardo de Lima Zollner
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-15T13:48:19Z (GMT). No. of bitstreams: 1 Trevizan_Giovanna_M.pdf: 992041 bytes, checksum: 788bad7f2b885488c459d8cc22f66468 (MD5) Previous issue date: 2010
Resumo: As reações alérgicas à ferroada de inseto resultam de resposta exacerbada do sistema imune, com produção de elevados níveis de anticorpos IgE alérgeno-específicos e padrão de citocinas Th2. A diferenciação de linfócitos Th2 e a secreção de citocinas por estas células são reguladas pelo fator de transcrição GATA-3. A ligação da IgE ao seu receptor de alta afinidade (Fc?RI) em mastócitos e basófilos, promove a liberação de mediadores inflamatórios. Muitos estudos demonstram a eficácia da imunoterapia específica na dessensibilização e no desenvolvimento de tolerância em indivíduos com quadros graves de hipersensibilidade à ferroada de insetos, sobretudo da classe Hymenoptera. A histamina é o principal mediador liberado durante a resposta alérgica; através da ativação de diferentes receptores (HR1, HR2, HR3 ou HR4) as células do sistema imune podem ser tanto inibidas como estimuladas. Via HR1, a histamina estimula principalmente linfócitos Th1, enquanto inibe linfócitos Th2 via HR2. O receptor 4 desempenha papel central na diferenciação de linfócitos Th2 e também é capaz de modular a produção de citocinas. A liberação de histamina é regulada por fatores de liberação de histamina (HRF), sendo que os HRF dependentes de IgE induzem a liberação de histamina na fase tardia das reações alérgicas. Considerando-se todas essas informações, o objetivo do presente trabalho foi avaliar os efeitos modulatórios da imunoterapia na expressão gênica dos receptores de histamina (HR1, HR2 e HR4), fatores de liberação de histamina (HRF) e cadeia ? do receptor de alta afinidade de IgE, além da expressão protéica do fator de transcrição GATA-3, em células linfomononucleares de pacientes alérgicos ao veneno de abelha. As células foram isoladas de pacientes submetidos à imunoterapia, em diferentes períodos do tratamento (Pré, 1, 3, 6, 12, 18 e 24 meses), após injeção subcutânea, e submetidas à cultura por 72 horas, com estimulo de veneno de abelha a 1 ng/ml. Indivíduos não alérgicos foram estudados como grupo controle. Com objetivo de avaliar a expressão gênica foram realizadas extração de RNA, seguida de síntese de cDNA e PCR, para avaliação da expressão protéica, utilizou-se a técnica de imunofluorescência. A expressão gênica de HR1 e HR4, assim como de HRF e da cadeia gama do Fc?RI foi significativamente reduzida ao final do período analisado. O receptor 2 de histamina não apresentou alterações bem definidas após 24 meses de imunoterapia. O fator de transcrição GATA-3 apresentou diminuição significativa na expressão a nível protéico. Nossos resultados demonstram que a imunoterapia específica ao veneno de abelha foi capaz de modular elementos envolvidos na resposta imune
Abstract: Allergic disease is an abnormal response from the immune system, with high levels of allergen specific IgE antibodies and Th2 pattern of cytokines. Development of Th2 cells and the production of cytokines are regulated by transcription factor GATA-3. Binding of IgE to its high affinity receptor (Fc?RI) in mast cells and basophils induces inflammatory mediators' release. Many studies have shown the efficacy of specific immunotherapy. Histamine is an important mediator in allergy, through activation of distinct histamine receptors (HR1, HR2, HR3 or HR4) in the immune system; cells can be either stimulated or inhibited. Histamine can stimulate, by HR1 receptor, especially Th1 response, and inhibit particularly Th2 cells through HR2 activation. HR4 plays a central role in Th2 polarization and also modulates cytokine profile production. IgE-dependent histamine releasing factors (IgE-HRF) induce histamine release in late phase reaction. In regard of this information, the aim of this study was to evaluate the modulating effects of specific immunotherapy in gene expression of histamine receptors (HR1, HR2 and HR4), histamine releasing factor (HRF), in patients with allergy and the gama chain of Fc?RI, and also GATA-3 protein levels. Bee venom allergic subjects underwent specific bee venom immunotherapy (VIT) in different stages of treatment (Pre, 3, 6, 12, 18 and 24 months) were studied. Peripheral blood mononuclear cells were isolated after subcutaneous venom injection and submitted to culture for 24, 48 and 72 hours stimulated with 1ng/ml of bee venom. In parallel healthy subjects were studied as well. Total RNA extraction, followed by cDNA synthesis and PCR were used to evaluate gene expression; GATA-3 protein expression was analyzed by immunofluorescence assay. Data from all time of cell culture - 24, 48 and 72 hours - were grouped and analyzed. Gene expression from HR1 and HR4 and also HRF and ? chain of Fc?RI were significantly reduced at the end of 24 months of immunotherapy. Histamine receptor 2 didn't show well established alterations. For transcription factor GATA-3 significant decrease at protein level was observed. Together, our results indicate that bee venom specific immunotherapy was able to modulate some of the elements involved in the immune response
Mestrado
Ciencias Basicas
Mestre em Clinica Medica
APA, Harvard, Vancouver, ISO, and other styles
9

Schiener, Maximilian [Verfasser], Simon [Akademischer Betreuer] Blank, Simon [Gutachter] Blank, and Michael [Gutachter] Sattler. "Improved Diagnosis and Therapy of Hymenoptera Venom Allergy by Component-Resolved Approaches / Maximilian Schiener ; Gutachter: Simon Blank, Michael Sattler ; Betreuer: Simon Blank." München : Universitätsbibliothek der TU München, 2018. http://d-nb.info/1178672123/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Röver, Anne Constanze. "Phänotypische und funktionelle Charakterisierung peripherer B-Zellen während Wespengiftimmuntherapie." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2001. http://dx.doi.org/10.18452/14646.

Full text
Abstract:
Die Wespengiftallergie stellt eine typische allergische Sofortreaktion dar. Für diese IgE-vermittelten, pathologischen Immunreaktionen ist die spezifische Immuntherapie (IT) die einzige zur Zeit zur Verfügung stehende kausale Therapie. Die Wirkmechanismen sind trotz intensiver Bemühungen weiterhin nicht vollständig aufgeklärt. Als wichtigste These wird zur Zeit eine Verlagerung des pathologischen, TH2-dominierten Zytokinmilieus in Richtung "normales" TH1-Milieu diskutiert. Es wurde auch eine reduzierte Mediatorfreisetzung von Effektorzellen, eine verminderte Leukozytenproliferation, eine verminderte Endorganantwort und charakteristische Ig-Titer-Veränderungen mit initialem Anstieg und längerfristigem Abfall des sIgE und Anstieg des sIgG4 beschrieben. In der vorliegenden Arbeit wurde der Einfluß der IT auf periphere B-Zellen hinsichtlich ihrer Ig-Produktion und ihres Phänotyps untersucht. 15 Patienten mit systemischen Reaktionen nach Wespenstich, Nachweis von spezifischem IgE und positivem Hauttest, bei denen eine Schnell-Immuntherapie eingeleitet wurde, wurden vor Beginn der Therapie (Tag 1), am Tag ihrer Entlassung (Tag 6), also einen Tag, nachdem die Erhaltungsdosis von 100 µg erreicht wurde, und vor der 2. ambulanten Allergeninjektion am 26. Tag untersucht. Die Expression von CD5, CD23, CD32, CD40, CD54, CD86, CD95, HLA-I-ABC und HLA-II-DR wurde auf peripheren mononukleären Blutzellen durchflußzytometrisch bestimmt. Anti-CD19 FITC wurde als spezifischer B-Zellmarker benutzt. Die Serum-Titer des Gesamt-IgE, Wespengift-spezifischen IgE und Wespengift-spezifischen IgG4 wurden mittels ELISA bestimmt. Zur statistischen Auswertung wurde der Wilcoxontest für nicht-parametrische, verbundene Daten benutzt. Die Expression von CD54, CD5, CD32 und HLA-II-DR wurde durch die IT signifikant und die von CD23 tendentiell modifiziert. So war die Expression dieser Moleküle auf der Oberfläche peripherer B-Zellen am Tag 6 im Vergleich zum Ausgangswert vom Tag 1 reduziert. Am 26. Tag wurden wieder Werte auf der Höhe der Ausgangswerte vom Tag 1 gemessen. Dagegen veränderte sich die Expression von CD40, CD86, CD95 und HLA-I-ABC während der untersuchten Zeitpunkte nicht. Die Ig-Titer veränderten sich in der für die IT charakteristischen Weise. So stieg nach 3 Wochen der Gesamt-IgE-, sIgE- und sIgG4-Titer hochsignifikant an. Die Expression der untersuchten Oberflächenmoleküle ist als Indikator für Veränderungen der Aktivationslage und des funktionellen Status der Zellen während der IT zu interpretieren. So spricht die Reduktion der Expression von CD32, CD54 und HLA-II für eine verminderte Aktivierungslage der peripheren B-Zellen. Ferner deutet die Reduktion von CD5 und CD32 auf eine Anergie der B-Zellen hin. Durch die reduzierte Expression von CD23 und CD54 könnte die T-B-Zell-Interaktion verschlechtert werden, die für die Effektorfunktionen beider Zellen bedeutsam ist.Einen wesentlichen Beitrag zur Wirksamkeit der IT könnte auch die verminderte Expression des HLA-II leisten, da HLA-II für die Ag-Präsentation essentiell ist. In dieser Arbeit wurde gezeigt, daß die spezifische Immuntherapie einen Einfluß nicht nur auf die Ig-Produktion der B-Zellen hat, sondern auch auf deren Phänotyp. Dies könnte Hinweise auf bisher nicht bekannte Mechanismen bieten, die an der Wirksamkeit der IT beteiligt sind.
Wasp-venom allergy is a typical IgE-mediated allergic reaction. Specific immunotherapy (IT) is the only currently available causal therapy for IgE-mediated allergies. The mechanisms responsible for the efficacy of IT are still not fully understood. So far, the main focus of research has been on changes of T-helper cell (TH) cytokine production with a shift from TH2 to TH1 cytokines. Reduced mediator secretion from effector cells of allergic reactions, decreased leukocyte proliferation, lowered responsiveness of end organs and changes in immunoglobulin levels have been reported as well. The purpose of this study was to investigate the influence of IT on phenotype and Ig-production of B-lymphocytes. 15 venom allergic patients with a history of systemic reactions after a wasp sting and venom-specific skin test reactivity as well as serum IgE were investigated before VIT (day 1), one day after reaching maintenance dose of 100 µg (day 6) during inpatient rush VIT, and again on day 26 during continued outpatient maintenance therapy. Changes in the serum levels of total IgE, allergen-specific IgE (sIgE) and sIgG4 were measured by ELISA. Expression of CD5, CD23, CD32, CD40, CD54, CD86, CD95, HLA-I-ABC and HLA-II-DR on double labeled B cells was studied by flow cytometry of peripheral blood mononuclear cells. On day 6, cell surface expression of CD54, CD5, CD32 and HLA-II-DR was decreased significantly in intensity and numbers of positive cells, compared to day 1, while on day 26, expression of these molecules approached again baseline levels. Furthermore, a trend to decreased CD23 was noted on day 6. No changes were observed for CD40, CD86, CD95 and HLA-I-ABC. Levels of total IgE, sIgE and sIgG4 showed a significant increase after 26 days of VIT. These data show that initiation of rush VIT has profound effects on B-cell phenotype and Ig-production. Reduced expression of surface molecules can be interpreted as a reduction of activation status of B-cells as well as reduced ability to present antigen and to costimulate other leukocytes. B cells may thus be additional direct or indirect targets of high dose antigen therapy and contribute to the efficacy of IT.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Venom allergy"

1

Lockey, Richard F., and Macy I. Levine. Monograph on insect allergy. 4th ed. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Insect sting allergy: Clinical picture, diagnosis, and treatment. Stuttgart: G. Fischer, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jolly, Elaine, Andrew Fry, and Afzal Chaudhry, eds. Allergy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199230457.003.0002.

Full text
Abstract:
Chapter 2 covers the basic science and clinical topics relating to allergy which trainees are required to learn as part of their basic training and demonstrate in the MRCP. It covers basic science, atopy, food, drug, latex, and venom allergy, urticaria and angio-oedema, anaphylaxis, approach to the immunosuppressed individual, immunodeficiency, immunology investigations, and immunological therapies.
APA, Harvard, Vancouver, ISO, and other styles
4

Monograph on insect allergy. 3rd ed. Milwaukee, WI: American Academy of Allergy and Immunology, Committee on Insects, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

1920-, Levine Macy I., Lockey Richard F, and American Academy of Allergy and Immunology. Committee on Insects., eds. Monograph on insect allergy. 2nd ed. [Milwaukee, Wis.]: American Academy of Allergy and Immunology, Committee on Insects, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wiese, Michael. Characterisation of Jack Jumper Ant Venom: Definition of the Allergic Components and Pharmaceutical Development of Myrmecia pilosula (Jack Jumper) Ant Venom for Immunotherapy. VDM Verlag, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nowak-Wegrzyn, Anna H., and Linda S. Coz. Update in Immunotherapy for Aeroallergens, Foods, and Venoms, an Issue of Immunology and Allergy Clinics of North America. Elsevier, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Venom allergy"

1

Przybilla, B., and J. Ring. "Hymenoptera Venom Allergy." In New Trends in Allergy III, 335–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-46717-2_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bermingham, William H., Alex G. Richter, and Mamidipudi T. Krishna. "Insect Venom Allergy." In Textbook of Allergy for the Clinician, 271–86. 2nd ed. Second edition. | Boca Raton : CRC Press, 2021.: CRC Press, 2021. http://dx.doi.org/10.1201/9780367854706-23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Golden, David B. K. "Duration of Venom Immunotherapy." In Stinging Insect Allergy, 141–51. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-46192-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ricketti, Peter A., and Richard F. Lockey. "Honeybee Venom Allergy in Beekeepers." In Beekeeping – From Science to Practice, 195–213. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-60637-8_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ruëff, Franziska, and Thilo Jakob. "Bee and Wasp Venom Allergy." In Braun-Falco´s Dermatology, 1–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 2021. http://dx.doi.org/10.1007/978-3-662-58713-3_28-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bonadonna, Patrizia, and Roberta Zanotti. "Venom Allergy and Management in Mastocytosis." In Mastocytosis, 157–74. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-27820-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jakob, T., S. Blank, and E. Spillner. "Benefits and Limitations of Recombinant Allergens in Diagnostics of Insect Venom Allergy." In Molecular Allergy Diagnostics, 341–62. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-42499-6_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Müller, U., M. Fricker, J. Carballido, and K. Blaser. "Successful Immuno Therapy with T-Cell Epitope Peptides of Bee Venom Phospholipase A2 in Two Patients with Honey Bee Venom Allergy." In New Trends in Allergy IV, 345–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60419-5_59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jutel, Marek, Mübeccel Akdis, Kurt Blaser, and Cezmi A. Akdis. "Anaphylaxis: Are Regulatory T Cells the Target of Venom Immunotherapy?" In Allergy Frontiers: Therapy and Prevention, 325–34. Tokyo: Springer Japan, 2009. http://dx.doi.org/10.1007/978-4-431-99362-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schroer, Brian. "Other Allergic Conditions: Venom Hypersensitivity, Drug Allergy, Chronic Urticaria/Angioedema, and Primary Immune Deficiency." In Allergies and Adolescents, 203–22. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-77485-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Venom allergy"

1

Kardas, Grzegorz, Agnieszka Daszyńska-Kardas, Marta Ambrożewicz, Agata Gabryelska, Radosław Wujcik, Piotr Kuna, and Michał Panek. "Significance of spirometry lung examination and complete blood count values in patients with asthma, chronic urticaria and Hymenoptera venom allergy." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2742.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kardas, Grzegorz, Agnieszka Daszyńska-Kardas, Marta Ambrożewicz, Agata Gabryelska, Radosław Wujcik, Piotr Kuna, and Michał Panek. "Analysis of psychological variables – depression levels, anxiety and mood traits - in patients with asthma, chronic urticaria and Hymenoptera venom allergy." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa2748.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Venom allergy' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography